NCT04620200 (MATISSE) is a Phase 2 clinical trial of Nivolumab in Cutaneous Squamous Cell Carcinoma, sponsored by The Netherlands Cancer Institute.

Who is sponsoring NCT04620200?

NCT04620200 is sponsored by The Netherlands Cancer Institute.

What drugs are being tested in NCT04620200?

Interventions in NCT04620200: Nivolumab, Ipilimumab.

What condition does NCT04620200 study?

NCT04620200 studies Cutaneous Squamous Cell Carcinoma.

Is NCT04620200 still recruiting?

NCT04620200 is currently completed. Last updated 11 August 2025.

Last reviewed 2025-08-11 · How we verify

NCT04620200: MATISSE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

Completed Phase 2 Last updated 11 August 2025

What this trial tests

Phase 2 trial testing Nivolumab in Cutaneous Squamous Cell Carcinoma in 50 participants. Completed in 7 January 2025.

Timeline

11 August 2020

Primary endpoint
7 January 2025

7 January 2025

Quick facts

Lead sponsor	The Netherlands Cancer Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	11 August 2020
Primary completion	7 January 2025
Estimated completion	7 January 2025
Sites	1 location across Netherlands

Drugs / interventions tested

Nivolumab (nivolumab) — full drug profile →
Ipilimumab — full drug profile →

Conditions studied

Cutaneous Squamous Cell Carcinoma — all drugs for Cutaneous Squamous Cell Carcinoma →

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, any sex, with Cutaneous Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous squamous cell carcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis.
Morgan HJ, Rees E, Lanfredini S, Powell KA, et al · · 2022 · cited 37× · PMID 36074574 · DOI 10.1172/jci150750
Cutaneous Squamous Cell Carcinoma: An Updated Review.
Jiang R, Fritz M, Que SKT. · · 2024 · cited 36× · PMID 38791879 · DOI 10.3390/cancers16101800
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma.
Boutros A, Cecchi F, Tanda ET, Croce E, et al · · 2021 · cited 28× · PMID 34513710 · DOI 10.3389/fonc.2021.733917
Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.
Stonesifer CJ, Djavid AR, Grimes JM, Khaleel AE, et al · · 2021 · cited 25× · PMID 34988009 · DOI 10.3389/fonc.2021.734354
The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities.
Amôr NG, Santos PSDS, Campanelli AP. · · 2021 · cited 25× · PMID 33634137 · DOI 10.3389/fcell.2021.636544
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.
Zelin E, Maronese CA, Dri A, Toffoli L, et al · · 2022 · cited 24× · PMID 35743435 · DOI 10.3390/jcm11123364
Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives.
Alberti A, Bossi P. · · 2021 · cited 24× · PMID 35070956 · DOI 10.3389/fonc.2021.727027
Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma.
García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, et al · · 2021 · cited 14× · PMID 34680282 · DOI 10.3390/cancers13205134

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Cutaneous Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
NCT07402616 — Ex Vivo Cutaneous SCC · NA · recruiting
NCT06875609 — ctDNA in Cutaneous Squamous Cell Carcinoma · recruiting
NCT06567314 — Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma · Phase 2 · recruiting
NCT06659146 — Thermotherapy in Addition to SOC Palliative Radiotherapy · NA · recruiting

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04620200 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
Last refreshed: 11 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04620200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing